Cerus to showcase INTERCEPT Blood System evidence at ISBT Congress
Cerus Corporation will present new evidence and innovations for its INTERCEPT Blood System at the 39th ISBT Congress in Kuala Lumpur from June 20-24, 2026. Key presentations include a symposium on pathogen inactivation and posters on bacterial contamination risks and operational efficiency. The company aims to highlight the technology's role in improving blood safety and patient care globally.
*this image is generated using AI for illustrative purposes only.
Cerus Corporation is set to showcase new evidence and global experience regarding its INTERCEPT Blood System at the 39th International ISBT Congress. The event is scheduled to take place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. The company's participation aims to highlight how blood centers utilize INTERCEPT technology to enhance blood safety, improve operational efficiency, and optimize patient care.
Christian Boutemy, vice president of international commercial operations at Cerus, emphasized the significance of the data being presented. He noted that the abstracts reflect a growing body of evidence supporting the INTERCEPT Blood System, alongside real-world experiences from blood centers across Asia. The presentations will feature innovations designed to optimize operations, such as reduced processing times using the LED-based INT200 illuminator and inventory management benefits linked to extended platelet shelf-life, as observed in Thailand.
A specific abstract from China will address persistent bacterial contamination risks in platelet components. This presentation reinforces the importance of a proactive pathogen-inactivation strategy in one of the world's largest transfusion markets. The full agenda includes a company-sponsored lunch symposium and various poster presentations detailing clinical and operational advancements.
Presentations and Abstracts
The following table outlines the key presentations and selected posters scheduled for the congress. All times are listed in Malaysian Time (MYT – UTC+8).
| Date / Time | Session / Presentation | Details |
|---|---|---|
| Sunday, June 21, 2026, 12:45–13:45 | Cerus Symposium | Pathogen Inactivation: The Proactive Choice to Improve Blood Safety |
| Chair | Pimpun Kitpoka, Thailand | |
| Presentations | Blood safety - Miles to go, before we sleep – Dr. Albert Farrugia | |
| INTERCEPT: Unmatched evidence and Proven patient benefits – Dr. Richard Benjamin | ||
| Monday, June 22, 2026, 17:15–18:45 | Poster Session | Select Posters of Interest |
| P363 | Preserved Fibrinogen Recovery and Stability of Low Plasma Volume Pathogen Reduced Cryoprecipitated Fibrinogen Complex. M. Gatmaitan, A. Paez, Y. Luo et al | |
| P373 | Reduction in Compound Adsorption Device Exposure Time for Pathogen Inactivated Platelet Components Treated With Amotosalen and an LED-Based Illumination Device. B. Dillon, A. Bernal, S. Crawford et al | |
| P370 | Introduction of Pathogen-Reduced Double-Dose Apheresis Platelets in a Tertiary Teaching Hospital in Thailand – Impact on Component Characteristics and Clinical Use. S. Khuenkham, N. Neeranatpaiboon, M. Picard-Maureau et al | |
| P376 | Amotosalen/UVA Inactivation of TTI-Associated Bacteria in Platelet Components. M. Krath, A. Engelhaupt, P. Nahata et al | |
| P478 | Bacterial Contamination of Platelet Concentrates in China. H. Weidong, C. Yuanfeng, X. Junfeng et al |
About Cerus Corporation
Cerus Corporation is dedicated to safeguarding the world's blood supply. Headquartered in Concord, California, the company develops and supplies technologies and pathogen-protected blood components to blood centers, hospitals, and patients. The INTERCEPT Blood System for platelets and plasma is available globally and holds both CE mark and FDA approval for these components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for producing Pathogen Reduced Cryoprecipitated Fibrinogen Complex, used to treat bleeding associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe and in late-stage clinical development in the U.S.
How will the new data presented at the ISBT Congress influence regulatory approval timelines for the INTERCEPT red blood cell system in Europe and the U.S.?
What potential market expansion opportunities does Cerus anticipate in China following the presentation on bacterial contamination risks in platelet components?
How might the operational efficiencies demonstrated by the INT200 illuminator impact Cerus's competitive positioning in the Asian blood safety market?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
